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Skin and soft tissue infections (SSTIs) are among the most common outpatient-acquired 
bacterial infections. In hospitalized patients, these infections are typically treated with 
intravenous antibiotics, which are switched to oral formulations during the course of 
treatment. The optimal time point for switching from intravenous to oral treatment is 
unknown and depends on numerous factors. In this study, we investigated an algorithm-
based switch from intravenous to oral antibiotics within 48 hours after treatment initiation. 
Methods:  
Hospitalized patients with uncomplicated SSTIs were screened for eligibility at 3 study sites 
(Langnau, Burgdorf, Biel/Bienne) from July 2019 to September 2020. Eligible participants with 
SSTIs were older than 18 years, required hospitalization because of the severity of the disease, 
were able to understand the study information and provided written informed consent. 
Exclusion criteria included antibiotic treatment 14 days or less before study inclusion, surgical 
site infections, impetigo without erysipelas/cellulitis, mastitis, nonbacterial infection or sterile 
skin inflammation (e.g., sweet syndrome, hypersensitivity reaction) and criteria consistent 
with “complicated” SSTIs (i.e., bacteraemia with Staphylococcus aureus or Pseudomonas 
aeruginosa, necrotizing fasciitis, skin abscess, septic shock or infection requiring intensive 
medical care, septic arthritis, osteomyelitis, tenosynovitis, bursitis, foreign body infection). 
Patients with a diabetic foot infection, classed on perfusion, extent, depth, infection and 
sensation (PEDIS) classification 3, were excluded. Other exclusion criteria included gram-
negative bacteria as the causative organism for the SSTI or an ecthyma gangrenosum.  
After 48 hours of intravenous antibiotics, patients were assigned to either the intervention 
group or the non-intervention group. In the intervention group, intravenous antibiotics were 
switched to oral formulations. The switch was performed after 1 or more of the following 
predefined criteria were fulfilled: decreased pain, normalization of PEDIS grade 4 criteria, 
decreased or steady inflammation parameters, decreased localization and a temperature of 
≤37.8°C for at least 24 hours. Patients in the non-intervention group were treated according 
the decision of the responsible physician. A total treatment duration of 5 to 10 days at the 
discretion of the treating physician was recommended. Follow-up phone calls were median 




Of 128 screened patients, 90 were included (73 in the intervention group and 17 in the non-
intervention group). Patients had a median age of 63 years, 64% were male, the majority 
had at least 1 comorbidity and the most affected site was the lower extremity (76.67%). In 
7.8% of patients (7 cases) a microorganism was identified in blood cultures or swabs from 
skin blisters (5 in the intervention group and 2 in the non-intervention group). The most 
common isolated microorganism was group C or group G Streptococcus.  
The median antibiotic treatment duration was 11 days in the intervention group and 15 days 
in the non-intervention group; the median intravenous treatment duration was 2 days in the 
intervention group and 4 days in the non-intervention group; and the median duration of 
hospitalization was 5 days in the intervention group and 7 days in the non-intervention 
group. Treatment failures were noted in 3 (4%) cases in the intervention group and in 1 case 
(6%) in the non-intervention group. 
Conclusions:  
In this prospective pilot trial on uncomplicated SSTIs in hospitalized patients, an algorithm-
based switch from intravenous to oral antibiotic treatment after a maximum of 48 hours was 
successful in 96% of cases. A prospective non-inferiority multicentre trial is required to 
confirm these results on level 1 evidence. 
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1. Background 
Skin and soft tissue infections (SSTIs) such as erysipelas rank among the most common 
outpatient-acquired bacterial infections. The infection manifests as swelling, redness and 
pain in the affected skin region. 
The incidence of SSTIs is approximately 20 cases per 10’000 person-years1,2. The infection is 
typically caused by beta-haemolytic streptococci (approximately 75%)3 and Staphylococcus 
aureus1. However, a causative pathogen is identified in only approximately 4% to 13% of 
cases1,4–7. Even when no microorganisms are identified, the clinical response to beta-lactam 
antibiotics is more than 95%2. Most frequently, the lower limb is affected2,5,8,9. 
In the geographic region of the study sites (Canton Bern), the prevalence of methicillin-
resistant S. aureus is low. Beta-haemolytic streptococci are uniformly susceptible to 
penicillin10. The Swiss empiric treatment recommendations for SSTIs (i.e., erysipelas and 
cellulitis without abscess formation or necrosis) include amoxicillin/clavulanate without 
surgery. In the case of penicillin allergy, oral cephalosporins or clindamycin are possible 
alternatives11. 
In many Swiss institutions, the treatment procedures for SSTIs are as follows. Depending on 
the severity of the disease, a decision for hospitalization or outpatient treatment is made. In 
hospitalized patients, intravenous empiric antibiotic treatment is initiated. The antibiotic 
treatment should be switched to an oral therapy, provided that there is a clinical response. 
The best time point for switching from intravenous to oral antibiotic treatment is, however, 
unknown. The recommended total treatment duration for SSTIs ranges between 5 and 14 
days6,12. 
An early switch from intravenous to oral antibiotic therapy may offer a substantial benefit to 
both the patient and the healthcare system, as shown in a recent study on bone and joint 
infections13. Nonetheless, no guidelines or uniformly accepted criteria are available on the 
duration of intravenous antibiotics prior to the switch to an oral formulation in SSTIs. Most 
clinicians use their clinical experience for decision making concerning this switch. However, 
criteria for switching to oral antibiotics for various other infectious diseases have previously 
been published 14–18 and have also been proposed by the Institute for Infectious Diseases at 
the University of Bern19.  
Although visible improvement of erythema may take longer, patients with an SSTI have 
symptomatic improvement within 24-48 hours after beginning antimicrobial therapy. A 
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recent study from Norway showed that concordance between the clinical and the 
biomedical response was strongest on days 2 and 3. Non-response at day 3 predicted 
treatment duration over 14 days, but not clinical failure20. This may indicate that clinical 
observations or biochemical variables show a delayed response in comparison to the 




2. Study aim, objectives and hypothesis 
We aimed to investigate the treatment outcome for uncomplicated SSTIs in hospitalized 
patients by using an algorithm-based switch from intravenous to oral antibiotics within 48 
hours after treatment initiation.  
The objective of the study was to estimate the efficacy of the antibiotic treatment concept in 
a pilot trial. 
We hypothesized that patients receiving intravenous antibiotic therapy for a maximum of 48 
hours followed by an oral formulation of antibiotic therapy (designated as the intervention 
group) would have the same clinical cure rate for SSTIs as patients not receiving such an 
intervention (designated as the non-intervention group: duration of intravenous therapy not 
restricted and decided at the discretion of treating team) and reported in the literature for 




3.1. Study design 
This was a prospective, non-randomized, multicentre pilot trial. It was designated as a pilot 
trial because the study aimed to test the proof of concept in clinical practice with a 
conceivable number of study subjects. The results will serve as data for a larger non-
inferiority trial (see section 3.9, sample size calculation). 
 
3.2. Study sites 
The study was performed in 2 centres in the Canton Bern (Regionalspital Emmental AG and 
the Spitalzentrum Biel). Regionalspital Emmental AG included 2 study sites (Hospital Langnau 
and Hospital Burgdorf). Hence, 3 institutions participated overall. 
The Regionalspital Emmental is within commuting range for more than 110'000 citizens and 
over 10'000 inpatients per year (2019)22 with a bed capacity of 177.5 (2018)23. Biel is within 
commuting range for 150’000 citizens and over 13’000 inpatients patients per year with a bed 
capacity of 224 in 2019 24. 
 
3.3. Study period 
The study was initiated at Regionalspital Emmental in July 2019 and in December 2019 at 
Spitalzentrum Biel. For this thesis, an analysis was performed prior to reaching the target 
sample size in September 2020. The study will, however, continue until the target sample size 
(at least 100 participants in the intervention group) is achieved. 
 
3.4. Study participants 
Eligible participants with SSTIs were older than 18 years, required hospitalization because of 
the severity of the disease, were able to understand the study information and provided 
written informed consent. Exclusion criteria included antibiotic treatment 14 days or less 
before study inclusion, surgical site infections, impetigo without erysipelas/cellulitis, 
mastitis, nonbacterial infection or sterile skin inflammation (e.g., sweet syndrome, 
hypersensitivity reaction), and criteria consistent with a “complicated” SSTI (i.e., 
bacteraemia with S. aureus or Pseudomonas aeruginosa, necrotizing fasciitis, skin abscess, a 
septic shock or infection requiring intensive medical care, septic arthritis, osteomyelitis, 
tenosynovitis, bursitis, foreign body infection). Patients with a diabetic foot infection, PEDIS 
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classification 3 (Appendix, page XIII), were excluded. Other exclusion criteria included gram-
negative bacteria as the causative organism for an SSTI or ecthyma gangrenosum.  
 
3.5. Screening and recruitment  
Eligible patients with SSTIs were consecutively screened in the emergency department or in 
the ward in the case of elective hospitalizations. Included patients had to provide 2 consent 
forms. The first form covered willingness to share their health-related data for study purposes, 
irrespective of antibiotic treatment concept. The second form asked for patients’ consent to 
participate in the study and in the intervention, provided that they fulfilled the predefined 
criteria for an early switch from intravenous to oral antibiotic treatment. Both consent forms 
were required within 48 hours following hospitalization. Patients who refused to provide the 
first consent form were excluded from the study. Patients who denied the second consent 
form or who were pregnant or lactating women were assigned to the non-intervention group. 
 
3.6. Antibiotic treatment and intervention 
Empiric intravenous antibiotics consisted of amoxicillin/clavulanate 2.2 g every 8 hours. In 
the case of allergies, cefuroxime 1.5 g was administered every 8 hours or vancomycin 15 mg 
per kilogram of body weight every 12 hours. In the case of renal insufficiency, antibiotic 
doses were adapted accordingly. Oral antibiotics consists of amoxicillin/clavulanate 1 g 3 
times per day or clindamycin 600 mg 3 times per day. 
The criteria for the switch to oral treatment included at least 1 of the following: clinical 
response to intravenous treatment, improvement of pain, improvement of erythema, 
diminishment of PEDIS 4 criteria, biochemical response (laboratory values), ability to 
swallow pills, or evidence of gastrointestinal absorption AND a body temperature of ≤37.8°C 
for at least 24 hours. Study participants fulfilling these criteria were assigned to the 
intervention group.  
Study participants who did not fulfill these criteria were assigned to the non-intervention 
group. In addition, prior to the switch to oral treatment, the local primary investigator 
evaluated clinical and laboratory values and was able to overrule the study intervention at 
his discretion. Study participants who remained on intravenous treatment because of the 
primary investigator’s decision were assigned to the non-intervention group. 
 11 
Figure 1 illustrates the study flow chart. The decision about total treatment duration was at 
the discretion of the responsible physician. 
 
    Figure 1 Study flow chart; IV: intravenous, SSTI: skin and soft tissue infection; AB: antibiotics 
 
3.7. Assessment 
Patient characteristics: The following patient characteristics were prospectively collected: 
age; gender; body mass index; cardiovascular comorbidities; renal function; presence of 
diabetes mellitus (and whether insulin dependent or not), allergies, immunosuppression, or 
cancer; alcohol consumption; and intravenous drug use. 
Clinical characteristics: The clinical characteristics obtained included pain at the site of 
infection, the presence of chills, body temperature, blood pressure (diastolic and systolic), 
heart rate, and oxygen saturation with or without oxygen. The intensity of the pain was 
solicited through the visual analogue scale, which ranged from 0 (no pain) to 10 (subjectively 
maximum possible pain).  
Skin and soft tissue infection: The anatomic body site of the infection was recorded, as well 
as the size of the skin lesion and, whenever possible, whether there was a portal of 
Emergent referral / presentation to emergency room Elective referral
Skin and soft tissue infection
Antimicrobial treatment according to in-house recommendation (IV)
Inclusion criteria fulfilled 
Exclusion criteria not present







Local principal investigator 
agrees to switch?
Yes No
Switch to oral AB
Assign to
intervention group
48 hours 48 hours
Patient consent also for switch?
Criteria for switch from oral to IV fulilled
Yes No
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entrance. The size of erythema (length ´ width) was registered 3 times during hospitalization 
(at day 1, prior to the start of oral antibiotic therapy and at discharge). 
Laboratory values: C-reactive protein (CRP) levels and white blood cell (WBC) counts were 
used to monitor laboratory treatment response. Blood sampling was obtained at the 
discretion of the treating team. We consecutively numbered the laboratory values 
retrospectively and assigned the day of blood sampling according to the following 
definitions: Lab 1 was assigned to values obtained at day 1 of hospitalization; lab 2 to values 
at day 3 or 4; lab 3 to values at day 5, 6 or 7; and lab 4 to values closest to day 30 after 
initiation of antibiotic therapy. If multiple values for a laboratory number designation were 
available, the mean was calculated and used. We always calculated the progression of CRP 
and WBC count percentages (decrease and increase of values) in comparison with those in 
lab 1. 
Microbiology: 4 blood cultures (2 aerobic and 2 anaerobic bottles) were obtained on the 
date of hospital admission. In patients with an obvious clinical portal of entrance or with 
blisters or bullae, a swab from the site of infection was obtained. The use of routine skin 
swabs was discouraged. 
Clinical monitoring: Clinical examination, and hence, clinical and laboratory response to 
antibiotic treatment, was performed daily until discharge. 
Use of antibiotics: The duration of intravenous and oral antibiotic treatment was measured as 
number of doses and days of treatment. 
Follow-up: Patients were contacted via telephone on day 39 after initiation of antibiotic 
treatment and interviewed with a predefined questionnaire (Appendix, page XVI). If 




The number and proportion of cured cases was calculated. The number of cured cases was 
measured as ‘total number of treated cases’ minus ‘the number of failed cases’. Clinical failure 
was defined as a new increase in symptoms during antibiotic treatment or after the switch to 
oral therapy, a second course of antibiotic therapy after discontinuing the first course, 
readmission within 30 days because of SSTI, or death. 
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3.9. Data collection, data monitoring, sample size calculation and statistical analysis 
Coded health-related data were entered by treating physicians in REDCap and stored at the 
server of the Clinical Trials Unit of the Faculty of Medicine of the University of Bern. All data 
were monitored for completeness by an independent physician who was not affiliated with 
the study centres.  
Considering the null hypothesis outlined in the aim, we calculated that 902 patients (451 in 
each group, 2-sided alpha risk 5%, power 90%) would be necessary to confirm the non-
inferiority hypothesis of oral treatment after 48 hours in a clinical trial. Because this is a pilot 
study, we aimed for 100 patients in the intervention group and did not define the patient 
numbers in the non-intervention group.  
Categorical parameters were compared with Fisher's exact test, and continuous variables 
were compared with the Mann–Whitney U test. A p value of <0.05 was considered 
statistically significant. We dispensed with a comparative analysis of the intervention and 
the non-intervention groups because of the small size of the non-intervention group; in 
addition, members of this group were sicker than those in the intervention group based on 
their non-compliance with the switch criteria and frequently larger skin lesions. The analysis 
and graphs were made with Stata/IC15.1 and GraphPad Prism8. 
 
3.10. Missing data 
As this was a prospective study and data monitoring was included, we aimed for a complete 
data set. Overall, the proportion of missing data was 5%. Analyses focused on variables with 
≤10% missing data. The overall proportion of missing data in the intervention group after 
switching to oral antibiotics was 10%. 
The variables with missing data are presented in Table 1. Compliance with consciously 









Missing data Intervention group (n=73) Non-intervention group (n=17) 
Localization 1     
Measurement 1 4 1 
Measurement 2 7 1 
Measurement 3 13 2 
      
Localization 2     
Measurement 1 0 - 
Measurement 2 1 - 
Measurement 3 0 - 
      
Pain     
Movement day 1 4 2 
Movement day 2 4 1 
Movement day 4 0 0 
Movement day 6 1 0 
Movement at date of discharge 4 1 
      
Rest day 1 2 1 
Rest day 2 0 1 
Rest day 4 0 0 
Rest day 6 1 0 
Rest at date of discharge  4 0 
      
Follow-up 1 0 
   
Table 1 Overview of missing data during the clinical course 
The erythema was also documented with a daily photograph in 97% (87/90) of the 90 
patients. 
 
3.11. Ethics and trial registration 
The Ethics Committee of the Canton Bern, Switzerland, approved this study (KEK 2019-
00558). This research project was conducted in accordance with the protocol of the 
Declaration of Helsinki25, the principles of Good Clinical Practice, the Human Research Act 
and the Human Research Ordinance26, as well as other locally relevant regulations. 




4.1. Study participants 
We screened 128 eligible patients and recruited 90 participants across 3 sites between July 
2019 and September 2020. 17 study participants were assigned to the non-intervention group 
and 73 to the intervention group. Their enrolment and assignment to the intervention and 


























Figure 2 Flow chart of patient screening, exclusion and enrolment 
 
Patients excluded 
n = 38 
Patients screened 
n = 128 
Switch criteria fulfilled 
- Decreased pain OR 
- Better general state OR 
- Decreased local finding OR 
- Normalization of the clinical PEDIS GRADE 4 criteria OR 
- Decreased or steady inflammation parameters 
AND 
- Temperature ≤37.8°C at least 24 hours 
11 Received antibiotics before 
6   non-understanding consent 
3   Refusing taking part 
5   Abscess, Ecthyma 
3   Arthritis, Bursitis, Tenosynovitis and 
     Foreign body infection 
3 Osteomyelitis, PEDIS Grad 3 
3 Mastitis 
1 Abacterial inflammation 
1 Necrotizing Fasciitis 
1 Septic Shock 
1 Case of bacteraemia with S. aureus or Pseudomonas 
 
Intervention group 
n = 73 
14  Switch criteria unfulfilled 
2    Overruled by principal investigator  
1    Refused switch, allowed data 
collection 
Non-intervention group 
n = 17 
Yes No 
Patients recruited 
n = 90 
 16 
4.2. Patient and clinical characteristics 
In the intervention group, 64% were men, the median age was 63 years (range 20 to 94 
years) and the median body mass index was 29.5 kg/m2 (range 17.5 to 64.3 kg/m2).  
The majority of the study participants had at least 1 of the following comorbidities: diabetes 
mellitus, cardiovascular disease, or kidney insufficiency (Table 2). More than 90% of the 
study population had no obvious immunosuppression. 3% (2/73) in the intervention group 
and 6% (1/17) in the non-intervention group were alcoholics. Of those who reported at least 
1 episode of SSTI in their patient history, 18% (13/73) were in the intervention group and 
29% (5/17) in the non-intervention group. Patient characteristics are presented in Table 2. 
 
Patient characteristics Intervention group Non-intervention 
group 
Total 









Age, y, median (range) 63 (20 to 94) 60 (37 to 76) 63 (20 to 94) 
BMI, kg/m2, median (range) 29.5 (17.5 to 64.3) 35.2 (25.3 to 44.1) 30.5 (17.5 to 64.3) 
Diabetes mellitus Type II (%) 
- With insulin therapy (%) 










Kidney insufficiency (KI) 
- No KI, G1 (%) 
- G2 (%) 
- G3a (%) 
- G3b (%) 
- G4 and G5 (%) 


























- 2 of them 
- all 3 











































Table 2 Characteristics and comorbidities of the intervention and non-intervention group; * One patient with 
cancer and another with immunodeficiency; BMI: Body mass index; PAOD: peripheral artery occlusive disease; 
CHD: coronary heart disease; SSTI: skin and soft tissue infection 
 
The clinical presentation varied considerably between study participants. The lower limb was 
the most commonly affected body site (77%), followed by the head (10%), upper limb (7%) 
and trunk/buttocks (7%). In 72% of the study subjects, a portal of entry (i.e., skin barrier 
break) was identified (Tables 3 and 4).  





Fever >38°C (%) 42 (57.53) 13 (76.47) 55 (61.11) 
Number of localizations (%) 
- 1  
- 2  













Localization 1/Affected site (%) 
- Lower limb right 
- Lower limb left 
- Buttocks 
- Trunk 
- Upper limb right 


























Localization 2/Affected site (%) 
- Lower limb right 
- Lower limb left 
- Buttocks 
- Trunk 
- Upper limb right 


























Localization 3/Affected site 
- Lower limb right 
- Lower limb left 
- Buttocks 
- Trunk 
- Upper limb right 


























Table 3 Localizations and affected sites of the intervention and non-intervention group 
Patient characteristics Intervention group Non-intervention 
group 
Total 
Local risk factors (%) 
- Status post-radiotherapy 
- Relapse 




















No chronic skin problems (%) 54 (72.60) 11(64.71) 65 (72.22) 
Portal of entry available (%) 52 (71.23) 13 (76.47) 65 (72.22) 
Rhagade (%) 9 (12.33) 2 (11.76) 11 (12.22) 
Tinea (%) 14 (19.78) 5 (29.41) 19 (21.11) 
Ulcer (%) 42 (57.53) 9 (52.94) 51 (56.67) 
Psoriasis (%) 4 (5.48) 0 (0) 4 (4.44) 
Atopic dermatitis (%) 1 (1.37) 0 (0) 1 (1.11) 
Toxic contact dermatitis (%) 0 (0) 0 (0) 0 (0) 
Allergic contact dermatitis (%) 1 (1.37) 0 (0) 1 (1.11) 
Other skin impairment (%) 18 (24.66) 7 (12.88) 25 (27.78) 
Table 4 Skin barrier impairment 
 
4.3. Microbiological results 
A causative microorganism was identified in 7 of 90 (7.8%) individuals, 5 (6.8%) in the 
intervention group and 2 (11.8%) in the non-intervention group. The organisms were 
identified in blood cultures in 4 cases (3 in the intervention group, 1 in the non-intervention 
group) and in swabs from blisters in 3 cases (2 in the intervention group, 1 in the non-
intervention group). All but 1 case with positive blood cultures revealed Streptococcus 
dysgalactiae, subspecies equisimilis (GCS or GGS). One case in the intervention group 
showed growth of Streptococcus agalactiae (GBS). The swabs from blisters revealed GCS or 
GGS in 2 cases (in 1 case, S. aureus was co-cultured) and Bacillus spp. in 1 case. Whether or 







4.4. Clinical course during antibiotic treatment 
4.4.1. Clinical assessment after 48 hours 
Consistent with the study protocol, all individuals in the intervention group showed clinical 
improvement after 48 hours of intravenous antibiotic treatment, and hence, qualified for a 
switch to oral antibiotic treatment. These participants revealed at least 1 of the predefined 
criteria (Table 5). In the non-intervention group, 82% (14/17) did not fulfill these switch 
criteria. 3 participants fulfilled these criteria but either refused to switch (1 study 
participant) or the switch decision was overruled by the primary investigator (2 study 
participants) (Figure 2). 
 
 





Fulfilled at least 1 of the following  
criteria only (%): 
- Better general state 
- Improvement of pain 
- Decreased local report 
- PEDIS grade 4 criteria not fulfilled 
- Lab inflammation parameters not increased 
73 (100) 2 (11.76) 75 (83.33) 
Fulfilled the following criterion only: temperature 
≤37.8°C for at least 24 hours (%)  
73 (100) 9 (52.94)  82 (91.11) 
Fulfilled both criteria 73 (100) 3 (17.65) 76 (84.44)) 















On hospital admission, the mean reported visual analogue scale score was 3 when 
participants moved the body site/extremity, and 2 when they rested the body 
site/extremity. During the course of hospitalization, these values improved to 1 and 0, 
respectively, in most patients belonging to the intervention group. In the non-intervention 





4.4.3. Size of the erythema 
In the intervention group, the SSTI affected 1 body site in 84% (61/73) of the patients. The 
median size of the erythema was 496 cm2 (range 0 to 7’380 cm2) on the day of hospital 
admission. In 15% (11/73) of the patients, 2 localizations were identified, and in 1 person 
(1%), 3 localizations were noted (Table 4). During treatment, the size of the erythema 
diminished. On the day of discharge, the median size had reduced to 100 cm2 (range 0 to 
2’480 cm2) (Figure 4a/4b). In patients with 2 SSTI localizations, the median size of the second 
erythema was 96 cm2 (range 0 to 968 cm2) on the day of admission and 6 cm2 (range 0 to 
342 cm2) on the day of discharge (Figure 5). 
In the non-intervention group, the median size on the day of admission was 1’020 cm2 
(range 0 to 3’896 cm2), which had reduced to a median of 550 cm2 (range 0 to 1’953 cm2) on 
the day of discharge (Figure 6). 
Illustrative cases within the intervention group are presented in Appendix 2, page XIX. 
Figure 3: Mean and SD of pain measured on visual analogue scale (VAS) (0: no pain, 10: maximal pain) 












Pain over time in the non-intervention group
Move
Rest

















Figure 4a: Size of the erythema at hospital admission date, before the switch and on date of discharge in  
the intervention group; 2 patients had no redness to measure 
 














































Figure 4b: Size of the erythema at hospital admission date, before the switch and on date of discharge in  
the intervention group; 
 
 




















































Figure 6 Size of the erythema on hospital admission date, before the switch and on date of discharge  






















































4.5. Laboratory course during antibiotic treatment in the intervention group 
The median CRP value of lab 1 was 99 mg/L (range 1 to 403 mg/L) and the median white 
blood cell (WBC) count was 10.95 G/L (range 4.43 to 38.30 G/L). Both parameters 
demonstrated decreasing dynamics. The values of lab 2 were median CRP level 85 mg/L 
(range 8 to 335 mg/L) and WBC count 7.49 G/L (range 3.15 to 15.20 G/L). At the last lab 
(preferably close to day 30, lab 4) the median CRP level was 6 mg/L (range 0 to 78 mg/L) and 
the median WBC count was 6.90 G/L (range 4.27 to 11.10 G/L). 
2% of intervention group participants (1/57) had an increase in the WBC count and 39% 
(22/56) had an increase in the CRP level from the first to the second measurement (i.e., from 
lab 1 at day 1 to lab 2 at day 3 or 4). 






















Figure 7: Biomedical response compared with the first measurement at hospital admission of the intervention group. 
Upper graphs: median and range; lower graphs: number of patients. CRP: C-reactive protein; WBC: white blood cell; Leuk: 
leukocyte 























1 = Day 1
2 = Day 3 and/or 4
3 = Day 5 to 7
4 = Follow-up











1 = Day 1
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3 = Day 5 to 7
4 = Follow-up











1 = Day 1
2 = Day 3 and/or 4

















































































4.6. Antibiotic treatment 
The median total antibiotic treatment duration in the study population was 11 days (range 6 
to 40 days). In the intervention group, the median duration was 11 days (range 6 to 42 days) 
and in the non-intervention group, it was 15 days (range 6 to 38 days).  
Consistent with the study protocol, the median and mean duration of the intravenous 
therapy in the intervention group was 2 days (range 1 to 9 days). Treatment of 1 patient 
assigned to the intervention group failed, and the patient was switched back from oral to 
intravenous treatment for 9 days. There was 1 documented protocol violation because 
physicians forgot to switch a patient from intravenous to oral treatment, resulting in the 
patient receiving 10 intravenous doses for 4 days, although an early switch was possible. The 
range of intravenous treatment duration without the treatment failure was 1 to 3 days in the 
intervention group. 
The non-intervention group received a median of 4 days (range 3 to 11 days) of intravenous 
therapy. The duration of oral therapy in the intervention group was a median of 9 days 
(range 4 to 38 days) and in the non-intervention group it was a median of 10 days (range 3 
to 27 days). 
 
4.6.1. Antibiotic compounds 
Intervention group 
Amoxicillin/clavulanate: 64 patients received a median of 6 doses (range 2 to 25 doses) of 
intravenous treatment for a median duration of 2 days (range 1 to 9 days). The median 
number of doses of oral formulation was 22 (range 8 to 74 doses) for a median duration of 
8.5 days (range 4 to 38 days).  
Cefuroxime: 5 patients received intravenous therapy because of an allergy (see section 
4.6.2). The median number of doses of intravenous formulation was 5 (range 3 to 6 doses) 
for a median duration of 2 days (range 1 to 2 days). 
Vancomycin: 1 patient received vancomycin (4 doses) over 2 days intravenously. 
Non-intervention group 
Amoxicillin/clavulanate: 15 of 17 patients received a median of 12 doses of intravenous 
therapy (range 7 to 42 doses) for a median duration of 4 days (range 3 to 11 days). 
Intravenous therapy was followed by a median of 26 doses (range 4 to 80 doses) of oral 
formulation over a median duration of 10 days (range 5 to 27 days).  
 26 
Cefuroxime and clindamycin: 1 patient received 10 doses of cefuroxime intravenously over 3 
days followed by oral clindamycin (7 doses over 3 days). 
Vancomycin and clindamycin: 1 patient received intravenous vancomycin for 7 days, 
followed by 23 days of oral treatment with clindamycin. 
 
4.6.2. Allergies 
7 individuals (9.6%) in the intervention group and 2 (12%) in the non-intervention group 
reported an allergy against an antibiotic compound. In the intervention group, 6 patients 
reported an allergy against penicillin or amoxicillin/clavulanate with a type 1 
hypersensitivity, 2 of them with a history of anaphylaxis. 1 patient reported an allergy 
against clindamycin. In the non-intervention group, 1 individual reported a history of 
anaphylaxis against penicillin. One study participant reported penicillin intolerance 
(diarrhoea).  
 
4.7. Duration of hospitalization 
The median duration of hospitalization was 5 days (range 1 to 37 days). Median 
hospitalization was 5 days (range 1 to 37 days) in the intervention group and 7 days (range 4 
to 17 days) in the non-intervention group. Figure 8 shows the alignment of duration of 
intravenous treatment, oral treatment and hospitalization.  
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Figure 8 Duration of antibiotic treatment and hospitalization in days in intervention group. IV: intravenous 
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4.8. Follow-up 
The follow-up phone call was performed on day 39 (median, range 28 to 90 days) in the 
intervention group and on day 39.5 (median, range 27 to 60 days) in the non-intervention 
group. There was 1 missing follow-up in the intervention group because the person was not 
available by phone. 
In the intervention group, 69 of 73 study participants were available for follow-up 
examination, and in the non-intervention group, 17 patients were available (see Figure 9).  
 
4.9. Outcome 
There were 3 failures in the intervention group. One patient received 48 hours of 
intravenous antibiotic therapy with amoxicillin/clavulanate, and then 11 days of oral 
therapy. One day after cessation of the antimicrobial therapy, an abscess was detected. The 
abscess was incised, and intravenous antimicrobial treatment was restarted and continued 
for 8 days. Two patients receiving cephalosporins experienced a relapse within 30 days. 
Two patients in the intervention group received antibiotic treatment for other reasons 
(arthritis and otitis media) during the follow-up period. These 2 cases were not categorized 
as treatment failures. Thus, the cure proportion in the intervention group was 96% and the 
failure rate was 4%. In the non-intervention group, there was 1 relapse (6%). 
In the follow-up interview, participants were asked about their subjective well-being in 
accordance with a predefined questionnaire (Appendix XVI). 86% (59/69) of the patients in 
the intervention group and 94% (16/17) in the non-intervention group reported a better 
general state in comparison to the date of hospital discharge.  
In addition, patients were asked about their level of pain. In the intervention group, 84% 
(58/69) of patients reported reduced or no pain, and in the non-intervention group, 82% 
(14/17) reported the same.  
Finally, patients were asked for their own judgment on the size of the erythema. Only 7% 
(5/69) in the intervention group and none (0/17) in the non-intervention group saw no 
considerable difference in size or redness of the erythema when comparing its size from the 
day of hospital discharge to the day of the telephone interview. However, 4 of the 5 patients 
in the intervention group reported a better general state and diminished pain. There were 
no adverse serious events, adverse events or rehospitalizations of the population during the 
study period. 
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Figure 9 Results of follow-up 
 
Included patients 
n = 90 
Missing to follow-up 
n = 1 
Follow-up intervention group 
n = 72 
Follow-up non-intervention group 
n = 17 
Follow-up pending 
n = 3 
 
Follow-up pending 
n = 0 
 
Failures 
n = 3 
No failures 
n = 66 
1 Reswitch from oral to intravenous therapy 
2 Restart oral antibiotic therapy after cessation 
Median days to follow-up after hospitalization 
39.5 days 
Median days to follow-up after hospitalization 
39 days 
Comparison with the date of discharge 
General state 
16 Better 
1   Same 
0   Worse 
Level of pain 
14 Reduced 
3   Same 
0   Worse 
Size of the erythema 
17 Smaller 
0   No difference 
Comparison with the date of discharge 
General state 
59 Better 
9   Same 
1   Worse 
Level of pain 
58 Reduced 
8   Same 
3   Worse 
Size of the erythema 
64 Smaller 
5   No difference 
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5. Discussion 
In this prospective pilot study on uncomplicated SSTIs, we aimed to investigate whether or 
not the switch from intravenous to oral antibiotic treatment within 48 hours is safe and 
effective.  
The recommended duration of antibiotic treatment for SSTIs is 5 to 14 days, depending on 
the clinical presentation. Clinical success is assessed as being when the SSTI improves during 
the treatment period6,12. In our study, the median duration of antibiotic treatment was 11 
days (11 days in the intervention group and 15 days in the non-intervention group). The 
median duration of hospitalization was 5 days in the intervention group and 7 days in the 
non-intervention group.  
A non-purulent, moderate SSTI, defined as the presence of systemic signs, should be initially 
treated with intravenous therapy6. This mode of therapy is recommended when the 
infection involves facial skin or when the peripheral circulation is impaired12. In this study, 
intravenous treatment was initiated in all patients because we included only those who 
required hospitalization because of the severity of infection. This severity is frequently 
classified as a moderate infection.  
Concerning the criteria for switching from intravenous to oral antibiotic treatment, there 
appear to be different viewpoints in the literature. Ahkee et al.15 used the following criteria: 
improvement in local signs and symptoms of an infection, guarantee of adequate 
gastrointestinal absorption, patient afebrile (>37.8°C) for at least 8 hours and leukocytosis 
decreased. The authors did not restrict this concept to SSTIs, however, as they included 
respiratory or urinary tract infections and intra-abdominal infection in their study15. A study 
from the Netherlands defined a switch after 48 to 72 hours from intravenous to oral therapy 
as being possible when the patient was hemodynamically stable with a trend towards 
normalization of body temperature and improvement in leukocytosis. They also included a 
broad range of infections in their study population (SSTIs and respiratory, urinary, abdominal 
and other infections)14. Mertz et al.18 used similar switch criteria for different types of 
infections (lower respiratory, urinary tract, intra-abdominal, systemic inflammatory response 
syndrome/fever of unknown focus, SSTIs, fever in neutropenia, bone or joint, endocarditis, 
central nervous system and other infections) after 48-72 hours of intravenous therapy. In 
their switch criteria, a body temperature of <38.0°C (tympanic) for at least 24 hours was 
mandatory. In the case of bacteraemia with S. aureus, an early switch was not allowed18.  
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All studies and recommendations agree, however, on the following criteria: Oral antibiotic 
therapy should be avoided in cases of severe infection during chemotherapy-related 
neutropenia. Moreover, enteral resorption must be present14.  
A study form Norway27 defined switch criteria for cellulitis for day 1 and day 3. On day 1, 
there had to be an improvement in clinical presentation (cessation of lesion spread and local 
inflammation defined by the intensity of erythema, warmth and tenderness). On day 3, 
there had to be an improvement in clinical presentation and a reduction of ≥20% in CRP 
levels compared with those on days 1 or 227. The results showed that, similar to the results 
of earlier studies, an improvement in local findings, a body temperature of >37.8°C for at 
least 24 hours, and a reduction in the WBC count and CRP values were useful criteria for an 
early switch, when gastrointestinal absorption was assumed. The strongest concordance 
between biomedical and clinical response occurred at days 2 and 327. 
The assessment in our study after 48 hours was intended to identify severe infections that 
required prolonged therapy and prolonged hospitalization. We used predefined criteria to 
assess the clinical (not the biomedical) response to antibiotic treatment. For decision 
making, we used predefined criteria for the term ‘uncomplicated’ and included them in the 
exclusion criteria. However, all patients had a level of severity that required hospitalization. 
All patients were also assessed by a senior physician after 48 hours to confirm or overrule 
the switch decision. Under these preconditions, the cure rate for SSTIs was 96%. Our study 
indicates that CRP dynamics may be delayed; thus, the CRP value may be not a useful 
criterion for the switch decision. We valued the clinical response. Most patients reported 
improvement in symptoms and fulfilled the predefined clinical criteria within 48 hours (84% 
of patients: 100% in the intervention group, 18% in the non-intervention group), irrespective 
of laboratory values. Nearly 40% of patients in the intervention group showed an increase in 
the CRP value but were switched to an oral formulation. Our pilot study also shows that the 
algorithm was applicable to over 80% of included patients.  
In other studies, a causative microorganism has been identified in only approximately 4% to 
13% of SSTI cases1,4–7. The causative microorganism for SSTIs was identified in 7% of cases in 
our study, similar to that reported in previous studies. The most frequent microorganisms in 
SSTIs are beta-haemolytic streptococci (73%)3,5,21 and S. aureus1,21. In recent years, GCS or 
GGS seems to be more prevalent than group A Streptococcus (GAS) (36 vs. 22 cases)21. In a 
Swedish study, GCS or GGS was the most commonly isolated microorganism (48%), followed 
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by GAS (26%), group B Streptococcus (GBS) (10%) and S. aureus (8%)5. In our study, GCS or 
GGS was found in 5 cases (2 in swabs and 3 in blood cultures) and GBS in 1 case. 
Our study has limitations. The measurement of the size of the erythema has an inter-
examiner bias and the measurement of the pain intensity is subjective, adding on an 
additional bias. As this was a pilot study, there was no randomization. We did not investigate 
whether there was an examiner bias when the switch criteria were assessed. In the follow-
up phone call, there is potential recall bias, in particular when considering the telephone 
interviews. Finally, the small sample size in the non-intervention group did not allow any 
statistical conclusions. None of the statistical tests were significant. 
 
Conclusions 
In this prospective pilot trial on uncomplicated SSTIs in hospitalized patients, an algorithm-
based switch from intravenous to oral antibiotic treatment after a maximum of 48 hours was 
successful in 96% of cases. The switch from intravenous to oral treatment could be 
performed in over 80% of the study population. We observed a shorter duration of 
hospitalization (median 2 days) in the intervention group than in the non-intervention group. 
The 2 study groups are, however, not comparable, because an algorithm with predefined 
criteria was applied to all study participants, leading to an uneven group distribution. A 
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